Status: Recruiting
Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults
This is a Phase 2, randomized, double-blind, controlled study designed to evaluate the safety, tolerability, immunogenicity, vaccine efficacy, and functional activity of Pfs230D1-CRM197 conjugate vaccine with R21 nanoparticle vaccine formulated on Matrix-M1. Participants (9-50 years of age) will be drawn from Bancoumana, Mali and the surrounding areas.
Participants needed: 1,200
Trial details
Phase: Phase 2Age: 9-50Biological sex: AllType: InterventionalSponsor: Serum Institute of India Pvt. Ltd.Updated: Nov 19, 2025Locations: 1
Eligibility criteria
Age:>/= 9 years old and </= 50 years old. [+11]
Pregnant and breastfeeding females. Pregnant, as determined by a positive urine... [+18]